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OBJECTIVE — In view of the previously described anti-inﬂammatory effects of insulin, we
investigated the potential suppressive effect of insulin on plasma concentrations and expression
of the chemokines, monocyte chemoattractant protein-1 (MCP-1) and regulated on activation
normal T-cell expressed and secreted (RANTES) and their receptors, chemokine receptor
(CCR)-2 and CCR-5, in mononuclear cells (MNCs). We also investigated the effect of insulin on
other chemokines.
RESEARCH DESIGN AND METHODS — Ten obese type 2 diabetic patients were
infused with insulin (2 units/h with 100 ml of 5% dextrose/h) for 4 h. Another 8 and 6 type 2
diabetic patients were infused with 100 ml of 5% dextrose/h or saline for 4 h, respectively, and
served as control subjects. Blood samples were obtained at 0, 2, 4, and 6 h.
RESULTS — Insulin infusion signiﬁcantly suppressed the plasma concentrations of MCP-1,
eotaxin,andRANTESandtheexpressionofRANTES,macrophageinﬂammatoryprotein(MIP)-
1, CCR-2, and CCR-5 in MNCs at 2 and 4 h. Dextrose and saline infusions did not alter these
indexes.
CONCLUSIONS — A low-dose infusion of insulin suppresses the plasma concentration of
key chemokines, MCP-1, and RANTES, and the expression of their respective receptors, CCR-2
and CCR-5, in MNCs. Insulin also suppresses the expression of RANTES and MIP-1 in MNCs.
These actions probably contribute to the comprehensive anti-inﬂammatory effect of insulin.
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O
ur work over the past few years has
shown that insulin exerts a compre-
hensive and rapid anti-inﬂammatory
effect as reﬂected in the suppression of in-
tranuclear nuclear factor-B and Egr-1
binding in peripheral blood mononuclear
cells (MNCs) and the plasma concentra-
tions of adhesion molecules and cytokines,
matrix metalloproteinases, tissue factor,
plasminogen activator inhibitor-1, and vas-
cularendothelialgrowthfactor(1–3).More
recently, a low-dose insulin infusion has
alsobeenshowntosuppresstheexpression
of several Toll-like receptors including
TLR1, 2, 4, 7, and 9 and PU.1, the major
transcription factor regulating their synthe-
sis(4).Thus,theanti-inﬂammatoryeffectof
insulin may be seen at several levels.
Recent work has shown that chemo-
kines are cardinal in the pathogenesis of
allinﬂammationbecausetheymediatethe
arrival of inﬂammatory cells to the site of
both acute and chronic inﬂammation.
Thus, the injection of endotoxin leads to
an increase in interleukin (IL)-8 for poly-
morphs and monocyte chemoattractant
protein-1 (MCP-1) for monocytes.
Chronic inﬂammation in atherosclerosis,
as observed in the arterial wall, is depen-
dent on the release of chemokines from
inﬂammatory cells in the atherosclerotic
plaque (5). MCP-1 is a major chemokine
that attracts more monocytes to the
plaque to enhance the inﬂammation and
thus facilitates the formation of foam cells
(6,7). MCP-1 is abundantly expressed in
atherosclerotic arterial lesions. The che-
motactic response of the MNC is depen-
dent on the presence of the chemokine
receptor-2 (CCR-2) on its surface (8). Re-
cent work has demonstrated that two
other cytokines, regulated on activation
normal T-cell expressed and secreted
(RANTES) (CCL-5) and fractalkine
(CX3CL-1),alsoplayanimportantrolein
atherogenesis (9). The deletion of either
thecytokinesortheirrespectivereceptors
leads to a marked reduction in atherogene-
sisinanimalmodels(9).Thedeletionoftwo
of these three cytokines or their receptors
leads to an almost total elimination of ath-
erosclerosis(9).Clearly,theirroleinathero-
genesis is of extreme importance.
IthasbeenshownthatMCP-1,secreted
by the adipose tissue macrophages, medi-
atesthemovementofthecirculatingmono-
cytes to the adipose tissue to further
enhance the inﬂammatory potential of the
adipose tissue (10,11). The chemotactic re-
sponse of the MNC is dependent on the
presence of CCR-2 on its surface (8).
MCP-1 is the major natural ligand for this
receptor (12). Most chemokines have at
least four cysteine residues, two near the
NH2 terminus, one near the COOH termi-
nus, and one in the middle. The two near
the NH2 terminus may either be next to
eachother(CCmotif)orbeseparatedbyan
amino acid (CXC) motif. MCP-1, RANTES,
andeotaxinbelongtotheCCclass,whereas
fractalkine, IL-8, and stromal-derived fac-
tor-1 (SDF-1) possess the CXC motif (12).
CCR-2 is a seven-transmembrane domain
G protein–coupled receptor whose activa-
tion leads to the rearrangement and intra-
cellular movement of actin, resulting in a
change in the shape of the cell and cellular
movement (12). CCR-5, a similar receptor,
is found on monocytes and T-cells and has
RANTES as its ligand. Eotaxin and MIP-1
are other chemokines that bind to CCR-5
and are involved in allergic reactions and in
responses to HIV-1 infections, respectively
(13,14).
Our previous work has shown that
insulin suppresses MCP-1 concentrations
in plasma in obese individuals in vivo (1)
and its expression by human aortic endo-
thelial cells in vitro (15). Thus, chemo-
kine-basedinﬂammatoryprocessesmay
be suppressed by insulin. We have now
hypothesized that insulin suppresses
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mokines MCP-1, RANTES, eotaxin,
MIP-1, fractalkine, IL-8, and SDF-1 in
patients with type 2 diabetes. We also
hypothesized that it suppresses the ex-
pression of the chemokine receptors
CCR-2 (MCP-1 receptor), CCR-5 (RAN-
TES, eotaxin, and MIP-1 receptor),
CX3CR-1 (fractalkine receptor), CXCR-1
(IL-8receptor),andCXCR-4(receptorfor
SDF-1) in MNCs.
RESEARCH DESIGN AND
METHODS— Twenty-four obese pa-
tients with type 2 diabetes participated in
this study. They were taking stable doses
of oral antidiabetes medications. All pa-
tientsweretakingmetformin(1–2g/day),
and14patientsweretakingsulfonylureas
(5–10 mg/day glyburide or glipizide).
Noneofthesubjectswasreceivinginsulin
or thiazolidinedione therapy or taking
any antioxidant or nonsteroidal anti-
inﬂammatory drugs. Demographic data
for the patients are summarized in Table
1. After an overnight fast, 10 subjects (5
women) were infused with insulin (2
units/h) with 5% glucose and 20 mEq of
potassiumchloridefor4hfollowedby2h
of observation and washout. The blood
glucose level was maintained at a target
level of 80–130 mg/dl and was measured
every15min.Another8(4women)and
6 (4 women) subjects were infused with
either 5% glucose or normal saline
alone, respectively, at a rate of 100 ml/h
for 4 h and served as control subjects.
None of the patients had any hypogly-
cemic symptoms. Blood samples were
collected at baseline and at 2, 4, and 6 h
after the start of the infusion. The
protocol was approved by the Human
Research Committee of the State Uni-
versity of New York at Buffalo. An in-
formed consent form was signed by all
subjects.
MNC isolation
Blood samples were collected in Na-
EDTAandcarefullylayeredonLympholyte
medium (Cedarlane Laboratories, Hornby,
Ontario, Canada). Samples were centri-
fuged, and two bands separated out at the
top of the red blood cell pellet. The MNC
band was harvested and washed twice with
Hanks’ balanced salt solution. This method
yields 95% MNC preparation.
Quantiﬁcation of chemokines and
chemokine receptor expression
The mRNA expression of the chemokines
MCP-1, MIP-1, RANTES, eotaxin
(CCLs 2, 4, 5, and 11, respectively),
fractalkine, IL-8, and SDF-1 and the
chemokine receptors CCR-2, CCR-5,
CX3CR-1, CXCR1, and CXCR-4 was
measured in MNCs by RT-PCR: Total
RNA was isolated using the commer-
cially available RNAqueous-4PCR kit
(Ambion, Austin, TX). Real-time RT-
PCR was performed using an Mx3000P
QPCR system (Strategene, La Jolla, CA),
SYBR Green MasterMix (Qiagen, Valen-
cia, CA), and gene-speciﬁc primers for
CCRs and CCLs (Life Technologies,
Gaithersburg,MD).Allvalueswerenor-
malized to the expression of a group of
housekeeping genes including actin,
ubiquitin C, and cyclophilin A.
Western blotting
MNC total cell lysates were prepared, and
electrophoresis and immunoblotting
were performed as described before (1).
Monoclonal antibodies against CCR2 and
CCR5 (Abcam, Cambridge, MA) and ac-
tin (Santa Cruz Biotechnology, Santa
Cruz, CA) were used, and all values were
corrected for loading to actin.
Plasma measurements
Glucoseconcentrationsweremeasuredin
plasma by a YSI 2300 STAT Plus glucose
analyzer (YSI, Yellow Springs, OH).
ELISA was used to measure plasma con-
centrationsofinsulin(DiagnosticSystems
Laboratories, Webster, TX), CCL-2/
MCP-1, CCL11/eotaxin, CCL5/RANTES,
andCCL4/MIP-1,IL-8,SDF-1,andfrac-
talkine (R&D Systems, Minneapolis,
MN).
Statistical analysis
Statistical analysis was conducted using
SigmaStat software (SPSS, Chicago, IL).
All data are presented as means  SEM.
Changes from baseline were calculated,
and statistical analysis was performed us-
ing one-way repeated-measures analysis
of variance (RMANOVA) with a Holm-
Sidak post hoc test. Two-factor RMANOVA
Table 1—Demographic data for patients at baseline
Insulin Glucose Saline
Age (years) 47.9  8.9 45.8  7.6 41.5  8.2
BMI (kg/m
2) 39.2  6.5 38.6  7.2 36.9  6.7
A1C (%) 7.00  0.8 7.30  0.9 7.5  1.1
Diabetes diagnosis
(years) 4.9  3.5 4.2  3.1 4.2  3.1
Fasting glucose
(mg/dl) 123  10 133  14 135  13
Fasting insulin
(U/ml) 20.9  10.9 27.6  5.6 20.6  5.5
Blood pressure
(systolic/diastolic) 137  4/102  3 131  4/94  3 133  5/95  4
Other medical
conditions Hypertension (6), hypothyroidism (2),
dyslipidemia (8), retinopathy (1)
Hypertension (5), hypothyroidism (1),
dyslipidemia (6)
Hypertension (4), hypothyroidism (1),
dyslipidemia (4), retinopathy (1)
Medications Metformin (all), sulfonylureas,
atenolol, atorvastatin, simvastatin
diltiazem, fosinopril, levothyroxine,
gemﬁbrozil, enalapril, metoprolol
Metformin (all), sulfonylureas,
atenolol, atorvastatin, simvastatin
diltiazem, fosinopril, levothyroxine,
gemﬁbrozil, enalapril
Metformin (all), sulfonylureas,
atorvastatin, diltiazem, fosinopril,
levothyroxine, gemﬁbrozil, Toprol,
enalapril, valsartan
Data are means  SEM.
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used for multiple comparisons between
different treatments.
RESULTS
Insulin and glucose concentrations
after insulin infusion
Plasma insulin concentration increased
from 20.9  10.9 to 50.5  22.4 U/ml
(P  0.001) during the insulin infusion,
whereas it fell slightly in the dextrose
groups from 27.6  5.6 to 22.9  6.5
U/ml at 4 h (NS) and in the normal sa-
line group from 20.6  5.5 to 17.9  4.7
U/ml at 4 h (NS). The mean blood glu-
cose concentrations changed from 122 
15 mg/dl at baseline to 111  10 mg/dl at
4 h (NS) after insulin infusion and from
133  14 mg/dl at baseline to 125  12
mg/dl at 4 h (NS) after dextrose infusion.
The blood glucose concentration did not
change in the saline group. Blood glucose
concentrationsatbaselineandat4hwere
notsigniﬁcantlydifferentamongthethree
groups.
Effect of insulin infusion on
chemokine receptors (CCR-2,
CCR-5, CX3CR-1, CXCR-1, and
CXCR-4) expression in MNCs
The mRNA expression of CCR-2 and
CCR-5 fell signiﬁcantly by 43  4 and
24  5%, respectively, at 4 h after insulin
infusion (P  0.05) (Fig. 1), whereas
there was no change in CX3CR-1,
CXCR1, and CXCR4 expression. There
was also a concomitant fall in CCR2 pro-
tein levels by 22  5% at 4 h after in
insulin infusion (P  0.05), whereas
CCR5 protein levels only showed a trend
toward a fall but did not reach statistical
signiﬁcance (Fig. 2). There was no signif-
icant change in the expression of these
receptors after glucose alone or saline
alone infusions.
Effect of insulin infusion on
chemokine concentrations (MCP-1,
eotaxin, MIP-1, RANTES, SDF-1,
and fractalkine)
After insulin infusion, there was a signiﬁ-
cant decrease in plasma concentrations of
Figure 1—Change in the expression of CCR2 (A) and CCR5 (B) in MNCs after 2 units/h insulin/dextrose infusion (Insulin), dextrose alone
(Dextrose), or saline alone (Saline) in obese type 2 diabetic patients for 4 h. Data are means  SEM. *P  0.05 by one-way RMANOVA (compared
with baseline). #P  0.05 by two-way RMANOVA compared with control groups.
Figure 2—Representative Western blots of changes in CCR2 and CCR5 protein (A) and percent
change in CCR2 (B) protein levels in MNCs after 2 units/h insulin/dextrose infusion (Insulin),
dextrose alone (Dextrose), or saline alone (Saline) in obese type 2 diabetic patients for 4 h. Data
are means  SEM. *P  0.05 by one-way RMANOVA (compared with baseline). #P  0.05 by
two-way RMANOVA compared with control groups.
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5%), and eotaxin (by 10 3%) at 4 h (P
0.05) (Fig. 3) but not in MIP-1, fracta-
lkine, or SDF-1 concentrations. There was
nosigniﬁcantchangeinplasmalevelsofthese
chemokines after dextrose or saline infusions.
Effect of insulin infusion on
chemokine expression in MNCs
We further examined the effect of insulin
infusion on chemokine expression in
MNCs. The mRNA expression of CCL4
(MIP-1)andCCL5(RANTES)fellsignif-
icantly by 26  10 and 22  8% below
the baseline, respectively (P  0.05) (Fig.
4) after insulin infusion, but not after glu-
cose or saline alone, whereas that of
MCP-1, fractalkine, and IL-8 did not
change signiﬁcantly.
CONCLUSIONS — Our data show
for the ﬁrst time that a low-dose insulin
infusion in type 2 diabetic patients sup-
presses plasma concentrations of MCP-1,
RANTES,andeotaxin.Thisoccursinpar-
allel with a signiﬁcant reduction in the
expressionofCCR-2andCCR-5inMNCs
within2hoftheinsulininfusion,ismain-
tained for the duration of the infusion,
and reverts to the baseline within2ho f
the cessation of the infusion. In addition,
insulin also suppressed the expression of
RANTES and MIP-1 in MNCs. Thus, in-
sulin exerts an inhibitory effect on che-
mokine mechanisms at three levels: the
expression and plasma concentration of
chemokines and the expression of their
receptors. These observations are consis-
tent with the previously demonstrated
suppression by insulin of MCP-1 in obese
individuals in vivo (1) and in endothelial
cellsinvitro(15).Incontrasttotheeffects
described above, insulin exerted no ef-
fects on the expression or plasma concen-
trationoffractalkine,IL-8,SDF-1,ortheir
receptors, CX3CR-1 CXCR-1, and
CXCR-4, respectively. It is of interest that
the cytokines and the receptors that were
suppressed by insulin have a CC conﬁg-
uration, whereas those that were not sup-
pressed, fractalkine and IL-8, and their
receptors have a CXC conﬁguration. The
biological and clinical signiﬁcance of this
difference is not clear at this time.
Insulin suppressed the plasma con-
centrationsofMCP-1butdidnotalterthe
expression of this chemokine in MNCs. It
is possible that it is secreted largely at
other sites. Indeed, the endothelium is
known to be its major source, and, as
statedabove,itsexpressioninhumanaor-
tic endothelial cells is suppressed by in-
sulin in vitro (15). CCR-2 is expressed on
monocytes, dendritic cells, and memory
T-cells and thus determines their move-
ments under the inﬂuence of the various
chemokines that bind to this receptor.
The clinical conditions likely to be af-
fected through the suppression of CCR-2
Figure 3—Change in plasma concentrations of MCP-1 (A), RANTES (B), and eotaxin (C) after
2units/hinsulin/dextroseinfusion(Insulin),dextrosealone(Dextrose),orsalinealone(Saline)in
obese type 2 diabetic patients for 4 h. Data are means  SEM. *P  0.05 by one-way
RMANOVA (compared with baseline). #P  0.05 by two-way RMANOVA compared with
control groups.
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and multiple sclerosis (8). MCP-1 is con-
sidered to have a nonredundant role in
the chemoattraction of monocytes to the
endothelium and in the transendothelial
transfer of the monocytes (16). Because
atherogenesis is dependent on the trans-
endothelialtransferofmonocytesintothe
intima, it is not surprising that deletion of
the MCP-1 gene leads to a reduction in
atherogenesis in experimental models of
atherosclerosis (17). Indeed, data from
the Diabetes Control and Complications
Trial-Epidemiology of Diabetes Interven-
tions and Complications (DCCT-EDIC)
show that intensive therapy with insulin
was associated with a reduction in the ca-
rotidintimal-medialthicknessandthein-
cidence of cardiovascular events (18). In
apolipoprotein E–deleted atherogenic
mice, the administration of insulin was
associated with a reduction in atherogen-
esis and oxidative stress (19). Further-
more, in genome-wide scans, MCP-1 has
beenshowntobeoneofthethreegenesto
be strongly associated with multiple scle-
rosis (20).
It is of interest that CCR-2 has re-
cently been shown to have an important
role in the pathogenesis of osteoporosis
(21). The deletion of CCR-2 results in the
protection of female mice from bone loss
after oophorectomy (21). It is therefore
possiblethattheMCP-1/CCR-2combina-
tion may play an important role in the
pathogenesisofpostmenopausalosteopo-
rosis.Thesuppressiveactionofinsulinon
MCP-1/CCR-2 implies that insulin may
have a potential anti-osteoporotic protec-
tive role in the bone. This ﬁnding is rele-
vant to the recently demonstrated
increase in fracture rates in patients with
type 2 diabetes independent of a reduc-
tion in bone mineral density (22).
On the other hand, CCR-5 is ex-
pressed on T-cells and monocytes, which
would respond to the chemokines listed
above that bind to CCR-5. CCR-5 is im-
portant in mediating transplant rejection
(12). Because RANTES is considered im-
portant in atherogenesis (23), the sup-
pressionofbothRANTESanditsreceptor
should have an inhibitory impact on
atherogenesis. Interestingly, CCR-5 also
serves as a coreceptor for HIV-1 for those
strains that are T-cell tropic. It would be
of interest to examine whether insulin re-
duces the entry of appropriate strains of
HIV-1 into T-cells.
The suppression of at least two
(MCP-1 and RANTES) of the three
(MCP-1, RANTES, and fractalkine) most
important chemokines involved in the
pathogenesisofatherosclerosisinpatients
with type 2 diabetes is relevant because
two-thirdsofmortalityinthisconditionis
attributable to atherosclerotic complica-
tions of coronary heart disease, cerebro-
vascular disease, and peripheral arterial
disease. The occurrence of insulin resis-
tance in this condition may result in an
increaseinthesechemokinesandtheirre-
ceptors and thus potentially promote
atherogenesis. Indeed, MCP-1 concentra-
tions are known to be increased in obese
individuals and in type 2 diabetic
patients.
In summary, a low-dose infusion of
insulin suppresses plasma concentrations
of MCP-1, eotaxin, and RANTES and the
expression of their respective receptors,
CCR-2andCCR-5,inpatientswithtype2
diabetes.Inaddition,itsuppressestheex-
pression of RANTES and MIP-1 in
MNCs. On the other hand, fractalkine,
IL-8, and SDF-1 and their respective re-
ceptorsarenotaffectedbyinsulin,atleast
during4hofinsulininfusion.Theoverall
anti-inﬂammatory effect of insulin thus
includes its suppressive effect on chemo-
kines and chemokine receptors with the
CC motif but not the CXC motif. These
Figure 4—Change in mRNA expression of CCL5 (RANTES) (A) and CCL4 (MIP-1)( B)i n
MNCs after 2 units/h insulin/dextrose infusion (Insulin), dextrose alone (Dextrose), or saline
alone (Saline) in obese type 2 diabetic patients for 4 h. Data are means  SEM. *P  0.05 by
one-way RMANOVA (compared with baseline). #P  0.05 by two-way RMANOVA compared
with control groups.
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they may contribute signiﬁcantly to the
treatment of a wide range of pathological
inﬂammatory processes, especially
atherosclerosis.
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